| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |